Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Biogen

US Approves New Drug to Treat Alzheimer's Disease

The US Food and Drug Administration on Friday approved a highly anticipated new drug designed to slow cognitive decline in patients in mild and early stages of Alzheimer's disease. The FDA approval of the drug, Leqembi, also known as lecanemab, comes just days after the regulatory agency was harshly criticized…

Asharq Al-Awsat

Alzheimer’s drug that slows disease progression approved by FDA

U.S. health officials have approved a new Alzheimer’s drug that modestly slows the brain-robbing disease

The Independent UK

FDA grants fast-track approval to experimental Alzheimer's drug

The FDA approved lecanemab, which has shown to slow the progression of Alzheimer's disease.

Axios

From analysis to the latest developments in health,
read the most diverse news in one place.

Alzheimer's drug that modestly slows disease OK'd by FDA

U.S. health officials have approved a new Alzheimer’s drug that modestly slows the brain-robbing disease

The Independent UK

2023 could be a banner year for prescription drugs

There's a large pipeline of promising yet expensive drugs that could get approved.

Axios

FDA’s approval of Biogen Alzheimer’s drug slammed in report

U.S. health officials’ approval process for Biogen Inc.’s controversial Alzheimer’s drug was “rife with irregularities,” raising serious concerns about protocol lapses at the agency, congressional investigators said.

Tribune News Service

Probe: Alzheimer's drug approval 'rife with irregularities'

The Food and Drug Administration's contentious approval of a questionable Alzheimer's drug is taking another hit

The Independent UK

Read news from The Economist, FT, and more,
with one subscription

House report questions FDA’s approval of Alzheimer’s drug

WASHINGTON — A joint investigation released Thursday by House Democrats identified unusual collaboration between Food and Drug Administration officials and drugmaker Biogen, highlighting potential problems in the agency’s approval of the controversial Alzheimer’s drug Aduhelm.

Tribune News Service

House report questions FDA's approval of Alzheimer's drug - Roll Call

House Democrats releases a report highlighting potential problems in the FDA's approval of Alzheimer's drug Aduhelm.

Roll Call

Lecanemab: Experimental drug is a ray of hope for Alzheimer's disease

On Nov. 30, Eisai and Biogen announced the results of their latest phase 3 clinical trial in Alzheimer’s disease. The verdict: an 18-month treatment with lecanemab slows functional and cognitive loss by 27 per cent in people with mild cognitive impairment or mild dementia due to Alzheimer’s disease. The study…

The Conversation

Lots of breakthroughs, still no cure. Do new dementia drugs bring us any closer?

We often hear about dementia breakthroughs in the news – new genes being discovered, new blood tests being developed, new drugs being tested.

The New Daily

Lots of 'breakthroughs', still no cure. Do the new dementia drugs bring us any closer?

We often hear about “dementia breakthroughs” in the news – new genes being discovered, new blood tests being developed, new drugs being tested.

The Conversation

Lisa Jarvis: That blockbuster Alzheimer’s drug? It’s not a cure

Biogen Inc. and Eisai Co. caused a stir in September when they announced positive results in a late-stage trial for a closely watched Alzheimer’s drug, lecanemab. Doctors tempered their excitement, though, until they could scrutinize the full peer-reviewed data.

Tribune News Service

Data shows drug slowing Alzheimer’s but doubts over effect remain

Lecanemab modestly slows disease’s inevitable worsening, but it remains unclear how much of a difference it will make.

Al Jazeera

Get all your
news in one place.

100's of premium titles.
One news app.

The New Daily

‘Momentous breakthrough’: New Alzheimer’s drug lives up to bold claims, with caveats

Data supports claims that a new drug reduced cognitive and functional decline in Alzheimer's patients by 27 per cent in a clinical trial.

WEKU

Study: Alzheimer's drug shows modest success slowing declines in memory, thinking

In a large study, the experimental Alzheimer's drug lecanemab reduced the rate of cognitive decline by 27 percent in people in the early stages of the disease.

Tribune News Service

Alzheimer's drug sparks hot debate over benefits as risks like brain bleeding emerge

Eisai Co. unveiled much-anticipated findings on its experimental Alzheimer’s drug, providing tinder for the hot debate over whether its modest efficacy is worth potential risks that include serious brain bleeding.

The Independent UK

Drug slows Alzheimer's but can it make a real difference?

New data shows an experimental Alzheimer's drug modestly slowed the brain disease's inevitable worsening

Get all your
news in one place.

100's of premium titles.
One news app.

Axios

Safety concerns hang over new Alzheimer's treatment

Two deaths linked to the drug may present a more complicated path to approval.

The Guardian - US

Gene therapy at $3.5m a dose approved for US adults with hemophilia B

Hemgenix frees patients from repeated treatments but initial cost makes it most expensive medicine in the world

The Guardian - UK

‘This looks like the real deal’: are we inching closer to a treatment for Alzheimer’s?

After years of setbacks, dementia researchers are getting excited about a new antibody drug called lecanemab. No one expects it to stop cognitive decline, but even slowing it would be a breakthrough

StockNews.com

2 Stocks You Could Keep in Your Portfolio Forever

Despite signs of inflation cooling in the United States, the IMF is not expecting the global economic picture to improve anytime soon. However, the cooling inflation might induce the Fed to ease the pace of rate hikes. As economic uncertainties remain, we think fundamentally solid stocks McDonald’s (MCD) and Biogen…

The Independent UK

Biogen tabs veteran pharma leader Viehbacher as next CEO

Biogen has picked former Sanofi CEO Christopher Viehbacher to become its next leader, as the drug developer continues to recover from its failed launch of the Alzheimer’s treatment Aduhelm

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For October 26, 2022

Upgrades

Benzinga

Biogen Whale Trades For October 20

A whale with a lot of money to spend has taken a noticeably bearish stance on Biogen. Looking at options history for Biogen (NASDAQ:BIIB) we detected 12 strange trades.

1 … 3 4 5 6

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Food and Drug Administration

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.